<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00533390</url>
  </required_header>
  <id_info>
    <org_study_id>CAAE-0017.1.009.000-03</org_study_id>
    <nct_id>NCT00533390</nct_id>
  </id_info>
  <brief_title>Randomized Clinical Trial to Assess the Efficacy and Safety of Concomitant Use of Rifampicin and Efavirenz 600 X 800mg</brief_title>
  <acronym>IPEC-EFV</acronym>
  <official_title>Anti-retroviral Efficacy, Tolerance and Other Pharmacologic Interactions of the Non Nucleoside Analog Efavirenz in Association With Rifampicin to Treat Tuberculosis and AIDS</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Oswaldo Cruz Foundation</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ministry of Health, Brazil</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Oswaldo Cruz Foundation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Rifampicin is a potent inducer of the CYP450 and decrease the plasmatic concentration of
      NNRTI and Protease Inhibitors. In our study we are going to compare the 600 an 800mg doses of
      efavirenz concomitant of rifampicin use to treat tuberculosis. The hypothesis is that the 800
      mg dose would be more adequate than the 600mg
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study consist in a open label randomized clinical trial comparing efavirenz 600mg QID
      versus efavirenz 800mg QID in patients with tuberculosis (treated with regimens including
      rifampicin) and AIDS diagnosis. The total duration of the study is 6 months for each patient.
      All eligible patient will be treated with a fist line regimen for tuberculosis according to
      Brazilian guidelines: rifampicin (600mg QID); isoniazid (400mg QID) e pyrazinamide (2g QID)
      during 6 months for a weight of 45 kg or more and adapted doses for persons with less than 45
      kg. For patients with previous history of TB therapy etambutol 1.200mg QID will be added to
      the regimen.

      Both groups will receive nucleoside reverse transcriptase inhibitors (NRTI)and a non
      nucleoside transcriptase inhibitor (NNRTI) to treat HIV. The ITRN of first choice will be
      zidovudine and lamivudine association. Patients presenting contra indication for the use of
      those drugs will receive others NRTI. The NNRTI is efavirenz (800 or 600mg).

      Antiretrovirals will be initiated 30 days after stable TB therapy. In case of adverse events
      during TB therapy that lead to treatment interruption, the study drugs will be delayed until
      the 30th day after triple therapy for TB. During HIV therapy NRTI can be changed in case of
      intolerance
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Lack of financial support and low inclusion rate
  </why_stopped>
  <start_date>January 2007</start_date>
  <completion_date type="Actual">October 2012</completion_date>
  <primary_completion_date type="Actual">October 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>proportion of patients with viral load &lt; 80 at the end of tuberculosis therapy proportion of adverse events in each group</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Immunologic reconstitution Genotyping resistance</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">130</enrollment>
  <condition>Tuberculosis</condition>
  <condition>HIV Infections</condition>
  <arm_group>
    <arm_group_label>EFAVIRENZ 800mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Efavirenz 800 mg (tablet) PO QD during 5 months associated with two nucleoside analogs during tuberculosis therapy with rifampicin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>EFAVIRENZ 600mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Efavirenz 600 mg (tablet) PO QD during 5 months associated with two nucleoside analogs during tuberculosis therapy with rifampicin</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>efavirenz</intervention_name>
    <description>600mg X 800mg QID during TB therapy with rifampicin associated with other antituberculosis drugs in patients concomitant treated for tuberculosis and AIDS</description>
    <arm_group_label>EFAVIRENZ 800mg</arm_group_label>
    <arm_group_label>EFAVIRENZ 600mg</arm_group_label>
    <other_name>Stocrin</other_name>
    <other_name>Sustiva</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adults with tuberculosis diagnosis, HIV positive.

          -  Agreement to avoid not allowed drugs during the trial, agreement to participate in the
             study (informed consent)

        Exclusion Criteria:

          -  Active liver disease

          -  Pregnancy or breast feeding

          -  CD4 counts &gt;350
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Valeria C Rolla, MD DSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>Instituto de Pesquisa Clinica Evandro Chagas, Fiocruz</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Maria Cristina S Lourenço, MSc</last_name>
    <role>Study Chair</role>
    <affiliation>Instituto de Pesquisa Clinica Evandro Chagas, Fiocruz</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Flávia M Sant'Anna, MSc</last_name>
    <role>Study Chair</role>
    <affiliation>Instituto de Pesquisa Clinica Evandro Chagas, Fiocruz</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mariza G Morgado, DSc</last_name>
    <role>Study Chair</role>
    <affiliation>Instituto Oswaldo Cruz, Fiocruz</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Pedro E Americano do Brasil, MD MSc</last_name>
    <role>Study Chair</role>
    <affiliation>Instituto de Pesquisa Clinica Evandro Chagas, Fiocruz</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Carolina S Smaltz, PhD student</last_name>
    <role>Study Chair</role>
    <affiliation>Instituto de Pesquisa Clinica Evandro Chagas, Fiocruz</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jose L Teixeira, Pharmacist</last_name>
    <role>Study Chair</role>
    <affiliation>Instituto de pesquisa Clinica Evandro Chagas</affiliation>
  </overall_official>
  <overall_official>
    <last_name>David J Hadad, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Federal University of Espirito Santo</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Reynaldo Dietze, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Federal University of Espirito Santo</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Moises Palaci, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Federal University of Espirito Santo</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Universidade Federal do Espirito Santo</name>
      <address>
        <city>Vitoria</city>
        <state>Espirito Santo</state>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>FIOCRUZ Instituto de Pesquisa Clinica Evandro Chagas</name>
      <address>
        <city>Rio de Janeiro</city>
        <zip>21040-900</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>November 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 19, 2007</study_first_submitted>
  <study_first_submitted_qc>September 20, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 21, 2007</study_first_posted>
  <last_update_submitted>November 7, 2015</last_update_submitted>
  <last_update_submitted_qc>November 7, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 10, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Oswaldo Cruz Foundation</investigator_affiliation>
    <investigator_full_name>Valeria Cavalcanti Rolla</investigator_full_name>
    <investigator_title>MD, PhD</investigator_title>
  </responsible_party>
  <keyword>efavirenz</keyword>
  <keyword>tuberculosis</keyword>
  <keyword>AIDS</keyword>
  <keyword>rifampicin</keyword>
  <keyword>efficacy</keyword>
  <keyword>safety</keyword>
  <keyword>Treatment Naive</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
    <mesh_term>Tuberculosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Efavirenz</mesh_term>
    <mesh_term>Rifampin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

